Polymorphisms in the Drug Transporter Gene ABCB1 Predict Antidepressant Treatment Response in Depression

Neuron

Volumn 57, Issue 2, 2008, Pages 203-209

  Uhr, Manfred ^a   Tontsch, Alina ^a   Namendorf, Christian ^a   Ripke, Stephan ^a   Lucae, Susanne ^a   Ising, Marcus ^a   Dose, Tatjana ^a   Ebinger, Martin ^a   Rosenhagen, Marcus ^a   Kohli, Martin ^a   Kloiber, Stefan ^a   Salyakina, Daria ^a   Bettecken, Thomas ^a   Specht, Michael ^a   Pütz, Benno ^a   Binder, Elisabeth B ^a   Müller Myhsok, Bertram ^a   Holsboer, Florian ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

DNA; HUMDISEASE; MOLNEURO

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DEXTRO VENLAFAXINE; DRUG METABOLITE; MIRTAZAPINE; PAROXETINE; TRIMIPRAMINE; UNCLASSIFIED DRUG; VENLAFAXINE;

ABCB1 GENE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DNA POLYMORPHISM; DRUG PENETRATION; GENE; GENOTYPE; HUMAN; KNOCKOUT MOUSE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REMISSION; TREATMENT RESPONSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DEPRESSION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; STATISTICS, NONPARAMETRIC;

EID: 38149003759     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuron.2007.11.017     Document Type: Article

References (32)

1. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., and Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 361-398
2. Binder E.B., Salyakina D., Lichtner P., Wochnik G.M., Ising M., Pütz B., Papiol S., Seaman S., Lucae S., Kohli M.A., et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Genet. 36 (2004) 1319-1325
3. Callen D.F., Baker E., Simmers R.N., Seshadri R., and Roninson I.B. Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum. Genet. 77 (1987) 142-144
4. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. 112 (2006) 457-473
5. Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Schwab M., Schaeffeler E., Eichelbaum M., Brinkmann U., and Roots I. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 69 (2001) 169-174
6. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., and Bertino J.R. Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 86 (1989) 695-698
7. Devault A., and Gros P. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol. Cell. Biol. 10 (1990) 1652-1663
8. Fisher R.A. Statistical Methods for Research Workers (1932), Oliver and Boyd, London
9. Grauer M.T., and Uhr M. P-glycoprotein reduces the ability of amitriptyline to cross the blood brain barrier in mice after a 10-day administration of amitriptyline. J. Psychopharmacol. 18 (2004) 66-74
10. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmöller J., Johne A., Cascorbi I., Gerloff T., Roots I., Eichelbaum M., and Brinkmann U. Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97 (2000) 3473-3478
11. Ito S., Ieiri I., Tanabe M., Suzuki A., Higuchi S., and Otsubo K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11 (2001) 175-184
12. Kim R.B. MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics 12 (2002) 425-427
13. Kim R.B., Leake B.F., Choo E.F., Dresser G.K., Kubba S.V., Schwarz U.I., Taylor A., Xie H.G., McKinsey J., Zhou S., et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70 (2001) 189-199
14. Kroetz D.L., Pauli-Magnus C., Hodges L.M., Huang C.C., Kawamoto M., Johns S.J., Stryke D., Ferrin T.E., DeYoung J., Taylor T., et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13 (2003) 481-494
15. McMahon F.J., Buervenich S., Charney D., Lipsky R., Rush A.J., Wilson A.F., Sorant A.J.M., Papanicolaou G.J., Laje G., Fava M., et al. Variation in the gene encoding the serotonin 2a receptor is associated with outcome of antidepressant treatment. Am. J. Hum. Genet. 78 (2006) 804-814
16. Murray C.J., and Lopez A.D. Evidence-based health policy - lessons from the Global Burden of Disease Study. Science 274 (1996) 740-743
17. *D report. Am. J. Psychiatry 163 (2006) 1905-1917
18. Sakaeda T., Nakamura T., and Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4 (2003) 397-410
19. Schinkel A.H., Wagenaar E., Mol C.A., and van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97 (1996) 2517-2524
20. Tanabe M., Ieiri I., Nagata N., Inoue K., Ito S., Kanamori Y., Takahashi M., Kurata Y., Kigawa J., Higuchi S., et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. 297 (2001) 1137-1143
21. Tang K., Ngoi S.M., Gwee P.C., Chua J.M., Lee E.J., Chong S.S., and Lee C.G. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12 (2002) 437-450
22. Tang K., Wong L.P., Lee E.J., Chong S.S., and Lee C.G. Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum. Mol. Genet. 13 (2004) 783-797
23. The ENCODE Project Consortium. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447 (2007) 799-816
24. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., and Willingham M.C. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84 (1987) 7735-7738
25. *D: implications for clinical practice. Am. J. Psychiatry 163 (2006) 28-40
26. Uhr M., and Grauer M.T. abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J. Psychiatr. Res. 37 (2003) 179-185
27. Uhr M., Steckler T., Yassouridis A., and Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 22 (2000) 380-387
28. Uhr M., Holsboer F., and Müller M.B. Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J. Neuroendocrinol. 14 (2002) 753-759
29. Uhr M., Grauer M.T., and Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol. Psychiatry 54 (2003) 840-846
30. Uhr M., Grauer M.T., Yassouridis A., and Ebinger M. Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in P-glycoprotein (abcb1ab) knock-out mice and controls. J. Psychiatr. Res. 41 (2007) 179-188
31. Westfall P.H., and Young S.S. Resampling-Based Multiple Testing (1993), John Wiley & Sons, New York
32. Wigginton J.E., Cutler D.J., and Abecasis G.R. A note on exact tests of Hardy-Weinberg equilibrium. Am. J. Hum. Genet. 76 (2005) 887-893